Skip to content
drillr.ai
Sign up

DNLI

Denali Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$22.28
−2.28%
Ask drillr

  • Aug 13, 2026, 16:13 UTC

    Denali Therapeutics launched AVLAYAH, an FDA-approved rare-disease therapy, and reported Q2 2026 revenue of $3.6 million, with projected Q3 revenue tripling due to accelerating patient uptake and payer coverage progress.

    Source:

  • Aug 6, 2026, 00:00 UTC

    Denali Therapeutics reported Q2 2026 financial results, including AVLAYAH net product revenue of $3.6 million and a net loss of $127.6 million.

    Source:

  • Aug 6, 2026, 00:00 UTC

    Denali Therapeutics sold a Priority Review Voucher for gross proceeds of $195 million in July 2026.

  • Jul 28, 2026, 00:00 UTC

    Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher to an unnamed large pharmaceutical company on July 27, 2026.

  • Jun 18, 2026, 00:00 UTC

    Denali Therapeutics Inc. agreed to sell its Rare Pediatric Disease Priority Review Voucher to an unnamed buyer for $195 million in cash.

    Source: